Hydrocortisone
Juvenile Myelomonocytic Leukemia
Explore 27 assets in Juvenile Myelomonocytic Leukemia →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06247787CT.gov A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Juvenile Myelomonocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hydrocortisone (this asset) | Children's Oncology Group | P1 | CC · 43 |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Thiotepa | St. Jude Children's Research Hospital | P3 | BBB |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Fludarabine | Children's Oncology Group | P3 | BB |
| Nivestim | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Cyclosporin A | Case Comprehensive Cancer Center | P3 | BB |
| Tacrolimus | Masonic Cancer Center, University of Minnesota | P2 | BB |
| Methotrexate | Children's Oncology Group | P2 | BB |
+36 more in the Juvenile Myelomonocytic Leukemia cohort
Other indications for Hydrocortisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Congenital Adrenal Hyperplasia | — | P4 | A · 81 |
| Childhood Acute Lymphoblastic Leukemia | — | P3 | BB · 68 |
| Adrenocortical Insufficiency | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Hydrocortisone in Juvenile Myelomonocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/hydrocortisone-juvenile-myelomonocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →